NCT07585591CompletedNot Applicable
Safety and Efficacy Evaluation of the XERF Device for Aesthetic Treatments
CynosureLutronic4 sites in 1 country40 target enrollmentStarted: January 20, 2025Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 40
- Locations
- 4
Study Overview
Brief Summary
The goal of this clinical study is to evaluate the safety and clinical effectiveness of the XERF noninvasive dual-frequency monopolar radiofrequency device for aesthetic improvement of facial aging, including fine lines and wrinkles, eyebrow lifting, and tightening of lax tissue in the lower face, submental area, and neck in healthy adults.
Up to 60 participants may be enrolled across up to five clinical sites in the United States. Participants receive XERF treatments using 6.78 MHz and 2.0 MHz energy; most undergo two sessions approximately four weeks apart (the protocol allows up to three). Standardized photographs are taken at baseline and follow-up visits.
Outcomes are assessed approximately 30 and 90 days after the final treatment. Effectiveness is evaluated using investigator-assessed global aesthetic improvement and participant-reported satisfaction, while safety and tolerability are assessed through procedural pain ratings and monitoring of adverse events throughout the study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 22 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •22 - 70 years old
- •Is willing to undergo study device use.
- •Has not received any toxin/filler in the treatment area in the past 6 months and agrees to not receive any throughout the study.
- •Willing to maintain current diet and exercise routine throughout study duration.
- •Understands and accepts the study condition to not receive any other procedures to the treatment area or to undergo any procedures, take any medications, supplements, or partake in any treatments indicated for weight loss or body contouring throughout the length of the study.
- •Understands and accepts the study condition of and agrees that he or she is able to be present for all study visits.
- •Willing to comply with all requirements of the study and is able to provide written informed consent.
Exclusion Criteria
- •Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding, or planning a pregnancy during the study period.
- •Has an implanted pacemaker, internal ventricular fibrillation controller (AICD), or any electrical device.
- •Has a metal implant that interferes with the transmission of energy to the electrical field.
- •Has received permanent fillers or facial implants.
- •Has a detected pathological abnormality.
- •Has a medical condition with potentially decreased function of the peripheral nervous tissue, such as but not limited to diabetes or multiple sclerosis.
- •Has an infection or infected tissue in the treatment area.
- •Unable or not willing to follow instructions for pre- and post-treatment care
- •Recent history of smoking (1 month)
- •Has unrealistic treatment expectations.
- •Has a history of herpes simplex in which the patient is not willing/able to receive preventive antiviral therapy.
- •Has a blood disorder and taking aspirin or blood disorder medications.
- •Has a malignant disease, cancer, or uncontrolled autoimmune disease.
- •Had previous surgical or cosmetic procedures in the treatment area in the last 3 months that could interfere with the treatment procedure (including but not limited to dermabrasion, chemical peels, laser skin resurfacing, fat augmentations, topical retinoids and radiofrequency treatments)
- •Currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months prior to entering this study
- •Has any condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study results, or may interfere significantly with the subject's participation.
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseCrohn DiseaseNCT07483099Eli Lilly and Company60
Completed
Not Applicable
easyEndoTM Lite Staplers and Loading Units in Thoracic SurgeryNCT07345013Ezisurg Medical Co. Ltd.900
Not yet recruiting
Unknown
A study to see if the Density Device helps improve loose skin in people losing weight with GLP-1/GIP medicines.CTRI/2025/10/096688Jeisys Medical Inc.18
Recruiting
Not Applicable
Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot StudyNCT07376837University Health Network, Toronto30
Not yet recruiting
Unknown
Post-Market Clinical follow-up study to evaluate safety and performance of Altius Buechel Pappas Primary Total Knee Replacement SystemCTRI/2025/04/085046TTK Healthcare Ltd (Ortho Division)200